Back to Business

AstraZeneca’s Etcamah trial misses primary endpoint

Business September 14, 2026 at 6:14 AM

AstraZeneca’s Etcamah trial misses primary endpoint

Investing.com

Read at Investing.com

More Stories

Goldplat declares special dividend of 0.87319 pence per share

Goldplat declares special dividend of 0.87319 pence per share

🇺🇸 Investing.com 32m ago

Eco Buildings nears completion of first Albania apartment block

Eco Buildings nears completion of first Albania apartment block

🇺🇸 Investing.com 35m ago

GSK’s Ris-Rez shows survival benefit in lung cancer trial

GSK’s Ris-Rez shows survival benefit in lung cancer trial

🇺🇸 Investing.com 39m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play